Abstract: The invention relates to a method for preventing or treating a disease or disorder that is associated with the MrgX2 receptor. The invention also relates to MrgX2 antagonists and physiologically acceptable salts thereof. The invention also relates to pharmaceutical compositions and dosage forms comprising an MrgX2 antagonist.

Abstract: The present invention relates to the use of a modified effect pigment in a radiation-curable coating composition, wherein the modified effect pigment is an effect pigment that is coated with at least one metal oxide layer to which at least one organic compound having one or more functional groups with a carbon-carbon multiple bond is bound. The invention is particularly suitable for metallic effect pigments, in particular aluminum pigments. A further part of the invention is the use of a modified effect pigment in a radiation-curable coating composition, wherein the modified effect pigment is an effect pigment to which at least one organic compound having one or more functional groups with a carbon-carbon multiple bond is bound. The radiation-curable, preferably UV-curable, coating compositions can in particular be lacquers, paints, printing inks, nail varnish or plastics.

Abstract: The present invention relates to the use of a modified effect pigment in a radiation-curable coating composition, wherein the modified effect pigment is an effect pigment that is coated with at least one metal oxide layer to which at least one organic compound having one or more functional groups with a carbon-carbon multiple bond is bound. The invention is particularly suitable for metallic effect pigments, in particular aluminum pigments. A further part of the invention is the use of a modified effect pigment in a radiation-curable coating composition, wherein the modified effect pigment is an effect pigment to which at least one organic compound having one or more functional groups with a carbon-carbon multiple bond is bound. The radiation-curable, preferably UV-curable, coating compositions can in particular be lacquers, paints, printing inks, nail varnish or plastics.

Abstract: The invention relates to adenine receptor ligands useful for treating, alleviating and/or preventing diseases and disorders related to adenine receptor function as well as pharmaceutical compositions comprising such compounds and methods for preparing such compounds. The invention is further directed to the use of these compounds, alone or in combination with other therapeutic agents, for the alleviating, preventing and/or treating diseases and disorders, especially the use as antinociceptive or neuroprotective drugs.

Abstract: Adenosine A2A receptor antagonists are useful for the preparation of medicaments against atrial fibrillation in mammals, including humans. It has been found that the adenosine A2A receptor is present in human atrial cardiomyocytes and participates in the pathological mechanisms underlying atrial fibrillation. An advantage of using A2A antagonists over other agents known in the art is that the A2A antagonists specifically target patients with atrial fibrillation.

Abstract: Adenosine A2A receptor antagonists are useful for the preparation of medicaments against atrial fibrillation in mammals, including humans. It has been found that the adenosine A2A receptor is present in human atrial cardiomyocytes and participates in the pathological mechanisms underlying atrial fibrillation. An advantage of using A2A antagonists over other agents known in the art is that the A2A antagonists specifically target patients with atrial fibrillation.

Abstract: A reticle-masking (REMA) objective for imaging an object plane onto an image plane has a condenser portion, an intermediate portion, and a field lens portion. The three portions together have no more than 10 lenses with a combined total of no more than five aspheric lens surfaces. Each of the three portions of the REMA objective has one or two aspheric lens surfaces.

Abstract: A reticle-masking (REMA) objective for imaging an object plane onto an image plane has a condenser portion, an intermediate portion, and a field lens portion. The three portions together have no more than 10 lenses with a combined total of no more than five aspheric lens surfaces. Each of the three portions of the REMA objective has one or two aspheric lens surfaces.

Abstract: Partial objective for illumination of an image field in an illuminating device of a microlithographic projection exposure apparatus, arranged between a aperture plane and an image plane. The partial objective comprises a first lens group and a second lens group with a lens with a first aspheric lens surface. The second lens group has at least a first lens with negative refractive power and at least a second lens with positive refractive power. The maximum field height Yimmax within the image field is at least 40 mm; the image-side numerical aperture is at least 0.15. The distribution of the chief ray angles PF over the field heights Yim within the image field is given by a pupil function PF(Yim), which consists of a linear contribution c1·Yim and a non-linear contribution PFNL(Yim), the non-linear contribution PFNL(Yim) being at least +15 mrad for the maximum positive field height Yimmax.